Latest News & Features
Europe
The UK government announced a change to the Patent Act on Tuesday that will allow parties to run drug trials without infringing other parties’ patents. 26 February 2013
Big Pharma
England’s Court of Appeal has affirmed a 2012 High Court ruling that pharmaceutical company Genentech’s patent covering human vascular endothelial growth factor antagonists is valid and has been infringed by Regeneron and Bayer Pharmaceutical’s drug Eylea. 25 February 2013
Americas
In a report published by Thomson Reuters on February 20, the BRICK nations were shown to be filing almost as many patents as the G7 nations in 2011. 25 February 2013
Americas
The US Court of Appeals for the Federal Circuit has affirmed a 2012 ruling that AstraZeneca’s patent for antipsychotic drug Seroquel XR is valid and has been infringed by companies selling competing generics. 19 February 2013
Asia-Pacific
A judge at Australia’s Federal Court has upheld Myriad Genetics’ patent covering a human gene mutation linked to breast cancer, in the country’s first court ruling on whether isolated genes can be patented. 18 February 2013
Asia
Israeli company Teva Pharmaceuticals could be forced to pay more than $2 billion in damages for selling a generic version of Nycomed and Pfizer’s heartburn reliever Protonix before the drug’s patent exclusivity expired in the US. 18 February 2013
Americas
A US judge has declared pharmaceutical company Bristol-Myers Squibb’s patent covering its hepatitis B treatment Baraclude obvious and invalid. 14 February 2013
Asia
India’s Patent Office has revoked pharmaceutical company Sugen and licensee Pfizer’s patent for the cancer drug Sutent, agreeing with Indian drugs maker Cipla that it lacks inventive step. 14 February 2013
Big Pharma
It seems an unlikely place for innovation, but Lille and its surroundings play host to a burgeoning life sciences industry. LSIPR visited to find out more. 1 February 2013
Asia-Pacific
The Federal Court in Australia has ruled in Cancer Voices Australia v. Myriad Genetics that isolated genetic material is patentable in Australia. Karen Sinclair explains the relevant issues. 1 February 2013